NEW YORK, Sept. 12, 2024 /CNW/ – Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced the initiation of the BREAKTHROUGH Study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with ..read more

TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to announce that it has been contracted as a supplier of MDMA to a ..read more

Vancouver, Canada, Sept. 06, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (“PCT”) for its ..read more

Vancouver, British Columbia–(Newsfile Corp. – September 9, 2024) – Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO), a leader in comprehensive mental health and wellness care, is excited to announce a research and patient care partnership with Sama Therapeutics for expanding access through novel technology. This collaboration marks the release of an advanced, proprietary ..read more

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of naturally derived psilocybin-based therapeutics, today announced that the first site initiation visit has been successfully completed at the first Australian clinical trial site for the Company’s Phase IIb study of nature derived (non-synthetic) psilocybin ..read more

Vancouver, British Columbia – TheNewswire – 29 August, 2024 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), is pleased to provide an update to shareholders.   Chief Executive Officer Justin Hanka provides a video update discussing the Company’s clinical trials currently dosing and underway, results from completed trials and plans for the future. The Company has ..read more

HOPE Therapeutics, a subsidiary of Wilmington, Del.-headquartered NRx Pharmaceuticals (Nasdaq: NRXP), has secured a $30 million deal to fund its planned acquisition of a network of psychiatric clinics focused on ketamine treatments. In a release, the Miami Beach, Fla., company said it had signed non-binding term sheets backed by a qualified lender to buy five clinics, located in the ..read more

Toronto, Ontario–(Newsfile Corp. – August 29, 2024) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the ..read more

The Multidisciplinary Association for Psychedelic Studies (MAPS) awarded Emory University researchers a $200,000 grant for a pilot study examining MDMA-assisted Massed Exposure Therapy for PTSD. The study is being conducted by Dr. Barbara Rothbaum and Dr. Jessica Maples-Keller at the Emory Healthcare Veterans Program in Atlanta, Georgia. Enrollment for this study is open to any civilian who meets ..read more

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that the registration statement pertaining to its previously announced $25 million equity line of credit (the “ELOC”) with White Lion Capital, LLC, (“White Lion”) on Form F-1 has been declared effective by the U.S. Securities ..read more